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Abstract
Background: The incidence of chronic subdural haematoma (CSDH) is increasing. Although surgery remains the
mainstay of management for symptomatic patients, uncertainty remains regarding the role of steroids. Hence, the
Dex-CSDH trial was launched in the UK in 2015 aiming to determine whether, compared to placebo, dexamethasone
can improve the 6-month functional outcome of patients with symptomatic CSDH by reducing the rate of surgical
intervention and recurrence rate.
Methods and design: Dex-CSDH is a multi-centre, pragmatic, parallel group, double-blind, randomised trial
assessing the clinical utility of a 2-week course of dexamethasone following a CSDH. Seven hundred fifty patients
were randomised to either dexamethasone or placebo. The primary outcome is the modified Rankin Scale at 6
months which is dichotomised to favourable (a score of 0–3) versus unfavourable (a score of 4–6).
Conclusions: This paper and the accompanying additional material describe the statistical analysis plan for the trial.
Trial registration: ISRCTN, ISRCTN80782810. Registered on 7 November 2014. http://www.isrctn.com/ISRCTN80782810.
EudraCT, 2014-004948-35. Registered on 20 March 2015.
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Background
Chronic subdural haematoma (CSDH) is a collection of
blood overlying the surface of the brain which is diag-
nosed on cranial imaging as a predominantly hypodense
or isodense collection in the subdural space on computed
tomography [1]. It is especially common in older patients
and can happen with only a minor injury to the head or
even in the absence of trauma. Symptoms that can be
attributed to a CSDH include headache, gait disturbance,
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falls, confusion, focal neurological deficit, speech distur-
bance, drowsiness, and seizures.
The incidence of CSDH is increasing [2]. In the UK,
approximately 5000 people aged over 65 years are diag-
nosed with a CSDH each year. In the National Health Ser-
vice (NHS), patients who are symptomatic usually have an
operation to evacuate the CSDH. Patients with very mild
symptoms or small collections are usually actively moni-
tored. Although about 80% of patients tend to recover well
from surgery, up to 20% of patients will have a recurrence
of the CSDH requiring further surgery. This significantly
reduces the chances of a good recovery.
One theory on the formation of a CSDH is that, fol-
lowing a traumatic injury, an inflammatory reaction is
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initiated which drives the growth of abnormal blood ves-
sels and fluid accumulation over the brain surface, sup-
ported by findings of high levels of inflammatory markers
within the CSDH fluid [3–6]. Steroids, such as dexametha-
sone, are thought to help dampen this inflammatory reac-
tion, allowing better resolution of the CSDH and lower
likelihood of recurrence. The Dex-CSDH (DEXametha-
sone in Chronic SubDural Haematoma) trial will deter-
mine whether steroids should be prescribed routinely for
patients with a symptomatic CSDH.
Methods and design
Dex-CSDH is a multi-centre, clinical phase III, ran-
domised, double-blind, placebo-controlled trial of dexam-
ethasone for up to 2 weeks on clinical outcome following
CSDH. In total, 750 symptomatic patients with a radio-
logical diagnosis of CSDH, recruited from neurosurgical
units (NSUs) based within the UK, were randomised to
a 2-week tapering course of either dexamethasone or
placebo stratified by site. The primary outcome mea-
sure was the modified Rankin Scale (mRS) at 6 months
(dichotomised to 0–3 and 4–6, as used in previous studies
[7, 8]), which was adapted from a validated questionnaire
[9]. The decision to dichotomise the mRS was based on
the clinical interpretability of the outcome and its poten-
tial value in future meta-analyses. Secondary outcome
measures sought a difference in the acute clinical course,
mortality, length of stay in hospital, discharge destination,
and adverse events and complications. All research staff
and outcome assessors were blinded. Full details of the
study design can be found in the protocol [10].
A sample size re-estimation was performed, using data
on 450 patients, due to uncertainty in the absolute
favourable outcome rate of the primary outcome (score of
0–3) in the control arm. The possible adaptations were to
either increase the sample size (up to a maximum of 1000)
or to stop the trial for futility if the revised sample size was
>1000; the original sample size would be retained if the
re-estimated sample size was <750. An Independent Data
Monitoring and Ethics Committee (IDMEC) reviewed the
sample size re-estimation and recommended the trial con-
tinue to recruit to the original target of 750 patients. The
investigators remained blinded to the analysis.
The statistical analysis plan (SAP) was written prior to
final analysis and unblinding in order to avoid report-
ing bias and data-driven results. The final outcomes will
be collected by July 2019, with the unblinded analy-
sis expected to take place in early 2020. The following
sections outline themain analyses featured in the SAP. Full
details are provided in Additional file 1.
Subject disposition
A Consolidated Standards of Reporting Trials (CON-
SORT) diagram will be produced to show patient disposi-
tion in accordance with the CONSORT statement [11]. A
mock CONSORT diagram is provided in Additional file 1.
Demographic and baseline variables
Summary statistics for a range of demographic and base-
line variables (health status, injury background, surgical
procedures, blood products given, concurrent illnesses,
prior and concomitant medications) will be produced.
Continuous variables will be summarised using the fol-
lowing descriptive statistics: n (non-missing sample size),
mean, standard deviation, median, maximum, and mini-
mum. The frequency and percentages (based on the non-
missing sample size) of observed levels will be reported for
all categorical measures.
Primary efficacy analyses
The primary analysis will estimate the absolute differ-
ence between the two treatment arms in the proportions
achieving a favourable outcome (mRS of 0–3 at 6months).
A normal approximation will be used to produce a 95%
confidence interval and two-sided P value to test the con-
firmatory hypothesis that there is no difference in the
primary outcome between the two treatment arms ver-
sus the alternative that there is a difference. The study
was adequately powered for this choice of analysis, which
makes as few assumptions as possible.
As a secondary analysis, a proportional odds logis-
tic regression model will be fitted to the original mRS
score, adjusting for the baseline covariates age and Glas-
gow Coma Scale (GCS) [12]. The model will not adjust
for the randomisation strata site, as the main reason for
stratification was investigational medicinal product (IMP)
management—to enable sites to keep a balanced supply of
drugs whilst maintaining the blinding. This will not signif-
icantly influence the outcome; the treatment was given by
a protocolised dosing regimen, so practice did not differ
between sites.
A number of exploratory subgroup analyses will be
undertaken by fitting logistic regressionmodels to the pri-
mary outcome and looking for a treatment interaction
effect with the following subgroups: site, age, timing of
head trauma, use of anticoagulants or anti-platelets, GCS
score at baseline, and unilateral versus bilateral CSDH.
Subjects will be analysed as randomised using both a
full analysis population (all randomised subjects excluding
those randomised in error) and a per protocol population.
The per protocol population will include subjects who
take at least 80% of their medication and exclude subjects
in the placebo group who receive >8mg of dexametha-
sone during the treatment course. The former condition
will be based on remaining pill count at the end of the
treatment period; the latter will be based on concomi-
tant medication information, which may not be recorded
accurately.
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The effect of treatment compliance on the primary out-
come will also be investigated in an exploratory manner,
including using an instrumental variables approach to
estimate the effect of compliance, measured as a continu-
ous percentage of medication taken.
Missing data
The sample size of non-missing values will be reported for
summary tables. For the primary and secondary outcomes
a graph showing the percentage of missing data will be
produced.
Patients who die during the conduct of the study will
receive an outcome score of “6-Dead” for all mRS assess-
ments occurring after the date of death. If there is less
than 15% missing data for the primary outcome, then a
complete case analysis will be used, which assumes data
are missing completely at random. If there is more than
15%missing data for the primary outcome, then a sensitiv-
ity analysis will be performed using the method described
in [13].
Secondary efficacy analyses
The secondary outcomes are:
• Number of CSDH-related surgical interventions
undertaken during the primary admission
• Number of CSDH-related surgical interventions
undertaken during subsequent admissions
• GCS at discharge and at 6 months (categorised as 0
to 7, 8 to 12, and 13 to 15)
• mRS at discharge and at 3 months
• Barthel Index [14] at discharge, 3 months, and 6
months
• European Quality of Life five-dimension, five-level
scale (EQ-5D-5L) [15–17] at discharge, 3 months,
and 6 months
• All-cause mortality at 30 days and 6 months
• Discharge information: length of stay in NSU, length
of stay in secondary care, discharge destination.
The number of surgical interventions undertaken dur-
ing the primary admission will be defined in two ways
and the analysis repeated for each: (1) including pre-
randomisation surgical procedures which occur within
the 72 h prior to randomisation, and (2) excluding pre-
randomisation surgical procedures. The clinical reason
for including pre-randomisation procedures is that the
exact timing of the first dose in relation to surgery is
thought to have little bearing on the pathophysiology;
rather it is the 2-week course of treatment that will have
the greatest impact. However, from a statistical point of
view it is preferable to exclude pre-randomisation proce-
dures from the outcome, as any differences in outcome
may simply be due to differences in pre-randomisation
procedures, and so this will be performed as a secondary
analysis.
The effect of treatment on each outcome will be mod-
elled using Poisson regression for count data (number of
CSDH surgical interventions, length of stay), proportional
odds logistic regression for ordinal data (GCS, mRS), lin-
ear regression for continuous data (Barthel Index, EQ-5D-
5L), and logistic regression for categorical data (discharge
destination). All models will be unadjusted for any base-
line covariates. Length-of-stay variables are calculated as
the total length of stay across all admissions and will
be treated as discrete counts (measured in days), and
therefore analysed using Poisson regression.
Post-randomisation subgroup analyses
As exploratory analyses, summary statistics (frequency
and percentage for the primary outcome) will be pro-
duced by treatment group for each of the following post-
randomisation subgroups:
• Recurrence versus non-recurrence of the CSDH
• Conservative management versus non-conservative
management (no surgery on any admission versus ≥1
operation)
• Trial conservative management (surgery within 7
days of randomisation versus surgery more than 7
days after randomisation versus no surgery at any
time point)
• Surgical intervention during primary surgery (burr
hole, mini-craniotomy)
• Drain during primary surgery versus no drain during
primary surgery.
Here recurrence is defined as a symptomatic recurrence
requiring re-operation of a previously evacuated ipsilat-
eral CSDH.
The recurrence rate is reported in the majority of surgi-
cal CSDH studies, and therefore its calculation will allow
cross-study comparisons [18].
A mediation analysis will be performed to look at both
the direct effect of treatment on the primary outcome
and the indirect effect of treatment via the mediator
variable recurrent CSDH, by estimating the causal param-
eters using parametric regression models for the mediator
and outcome. We will assume there are no unmeasured
confounders, and therefore results may be biased.
Safety analyses
Listings of adverse events (AEs) and serious adverse
events (SAEs) will be produced and will include informa-
tion on the following: the event, the onset and resolution
dates of the event, Medical Dictionary for Regulatory
Activities (MedDRA) preferred term, MedDRA system
organ class (SOC), causality, and outcome. The SAE listing
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will also include information on the severity and serious-
ness of the event.
The frequency and percentage of MedDRA SOC codes
will be reported. Plots showing the incidence of AEs and
SAEs and their relative risk (with 95% confidence interval)
based on the MedDRA SOC codes will also be produced.
Health economics
A health economics analysis is planned but is documented
in a separate health economics analysis plan.
Supporting information
Additional file 1 provides the full SAP.
Trial status
At the time of first submission, the Dex-CSDH trial had
finished recruiting the target of 750 patients and was in
follow-up.
Supplementary information
Supplementary information accompanies this paper at
https://doi.org/10.1186/s13063-019-3866-6.
Additional file 1: Statistical analysis plan: final analysis
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